<< Back to News

System Formulary Update
Dalbavancin (Dalvance)

Situation

In November 2022, a medication use evaluation (MUE) evaluating restriction adherence of formulary 
long-acting glycopeptides was presented to System Pharmacy and Therapeutics Committee. The recommendation was to restrict Dalbavancin (Dalvance) to outpatient/clinic use only.

Background

The following medication was reviewed: Dalbavancin (Dalvance)

Assessment/Recommendations

System P&T voted to include the dalbavancin (Dalvance) on the UNC Health Medication Formulary with restrictions to the following: 

• Outpatient/clinic use
• Inpatient use is restricted to patients who meet one of the following:
  • Antimicrobial Stewardship Program or Infectious Diseases Service approval
  • Patient unable to receive prolonged IV antibiotics and oral therapy is contraindicated or 
    not offered at on-site pharmacies for discharge prescribing 

Note: Stock of this formulary product may vary at individual entities

Formulary/Epic changes will Go-Live on Tuesday, April 4, 2023.